Compare Bristol-Myers Squibb Co (BMY) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.5 (market cap $116.30B), while iShares 1 3 Year Treasury Bond ETF trades at $82.01. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SHY | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Fixed Income |
52-Week High | $62.37 | $83.18 |
52-Week Low | $42.60 | $81.79 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SHY, a US Treasury bond ETF, trades at $81.79, down 0.11% with a bearish technical signal from moving averages. The fund maintains consistent dividend distributions of $0.24 per share scheduled through mid-2026. Current market sentiment reflects significant investor interest in cash and Treasury ETFs as bond yields rise, with nearly $100 billion flowing into cash ETFs according to recent reports.
The outlook for SHY remains tied to Federal Reserve policy decisions amid inflation concerns. While the ETF provides stable income through Treasury exposure, rising rate expectations could pressure short-term bond prices. Investors seeking yield may find competition from higher-yielding alternatives as Treasury yields approach 4% levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
